Inactief instrument

Andere talen Zymeworks Inc. Toronto S.E.

Aandelen

ZYME

CA98985W1023

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy	17/06
Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers	17/06
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers	17/06
Zymeworks Inc. Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer	10/06
Sector Update: Health Care Stocks Decline Premarket Monday	10/06
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy	10/06
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer	10/06
Zymeworks Announces Participation in Upcoming Investor Conferences	28/05
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME)	16/05
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	07/05
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results	02/05
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results	02/05
Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Unlocking the potential of antibody drug conjugates	01/05
Zymeworks Announces Participation in Upcoming Investor Conferences	30/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	28/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	20/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	12/04
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024	11/04
Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	08/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Zymeworks Inc. Toronto S.E.

Aandelen

ZYME

CA98985W1023

Andere talen

Filters